The proposed studies are designed to determine the role of blood-derived inflammatory monocytes/macrophages in mediating CNS damage in a two-hit model of status epilepticus (SE) and the mechanism(s) by which early therapy with biodegradable carboxylated monocyte-targeting PLG nanoparticles (IMPs) and regulatory T cells can be employed to limit neuropathology in SE. This work should provide critical pre-clinical information relevant to the translation and clinical testing of the IMP platform for the treatment of SE.
|Effective start/end date
|8/15/15 → 7/31/18
- National Institute of Neurological Disorders and Stroke (1R21NS094999-01)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.